Mentor Capital (MNTR) Invests in Leading-Edge Cancer Therapy &
Drug Development Companies
MNTR's objective is to help defeat cancer by funding $125 Million
into the best new cancer fighting companies. MNTR equity is targeted to the critical gap between non-profit
discovery and Big-Pharma sales.
To inject funds into the cancer companies (rather than trade in the
market) MNTR seeks to directly acquire and escrow $125 Million in shares from fifteen Cancer Index or other leading firms. Any resulting net exercise in
MNTR’s $125 Million in freely tradable warrants are paid out pro rata to the cancer
fighters under MNTR’s standard Long-Term Equity Funding Contract.
New Developments With The MNTR
Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013
Mentor Capital Telemedicine Investee Sales
Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
Mentor Capital Telemedicine
Investee Projects $1.0 Million Profit